These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702 [TBL] [Abstract][Full Text] [Related]
5. PET imaging of prostate cancer using carbon-11-choline. Hara T; Kosaka N; Kishi H J Nucl Med; 1998 Jun; 39(6):990-5. PubMed ID: 9627331 [TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma. Kälkner KM; Ginman C; Nilsson S; Bergström M; Antoni G; Ahlström H; Långström B; Westlin JE Nucl Med Biol; 1997 May; 24(4):319-25. PubMed ID: 9257330 [TBL] [Abstract][Full Text] [Related]
7. alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor. Heston WD; Kadmon D J Urol; 1986 Oct; 136(4):944-8. PubMed ID: 3093695 [TBL] [Abstract][Full Text] [Related]
8. Serial PET studies of human cerebral malignancy with [1-11C]putrescine and [1-11C]2-deoxy-D-glucose. Hiesiger E; Fowler JS; Wolf AP; Logan J; Brodie JD; McPherson D; MacGregor RR; Christman DR; Volkow ND; Flamm E J Nucl Med; 1987 Aug; 28(8):1251-61. PubMed ID: 3039083 [TBL] [Abstract][Full Text] [Related]
9. Is [1-11C]putrescine useful as a brain tumor marker? Hiesiger EM; Fowler JS; Logan J; Brodie JD; MacGregor RR; Christman DR; Wolf AP J Nucl Med; 1992 Feb; 33(2):192-200. PubMed ID: 1732439 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074 [TBL] [Abstract][Full Text] [Related]
11. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Kato T; Tsukamoto E; Kuge Y; Takei T; Shiga T; Shinohara N; Katoh C; Nakada K; Tamaki N Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1492-5. PubMed ID: 12397469 [TBL] [Abstract][Full Text] [Related]
12. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350 [TBL] [Abstract][Full Text] [Related]
13. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning. Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254 [TBL] [Abstract][Full Text] [Related]
14. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355 [TBL] [Abstract][Full Text] [Related]
15. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265 [TBL] [Abstract][Full Text] [Related]